Popular search terms:
Search Results Label
41 results found-
Month 00, 0000
For immediate release 31 July 2015 Update on Novartis influenza vaccines acquisition CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has secured the necessary
https://www.seqirus.com.au/-/media/seqirus-australia/news-docs/asx-announcement--update-on-novartis-flu-acquistion-31july-15f0.pdf -
Update on Novartis influenza vaccines acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has secured the necessary approvals required to proceed with the acquisition of the influenza vaccines business of Novartis and that it is working with Novartis to bring forward the close date for the transaction. The Company also said the new CSL subsidiary resulting from the acquisition will be called Seqirus.
https://www.seqirus.com.au/...influenza-vaccines-acquisition -
Seqirus | Partnership Opportunities
Seqirus stands with our partners on the front line of public health. We are the largest fully integrated commercialisation partner in Australia and New Zealand. Learn more.
https://www.seqirus.com.au/partnering -
Seqirus | Research & Development Efforts
Seqirus is working tirelessly to optimise our technology and implement transformational long-term approaches to influenza pandemic preparedness.
https://www.seqirus.com.au/r-and-d -
Seqirus | Vaccine Technologies
Seqirus employs both egg and cell-based manufacturing systems to ensure the availability of our influenza vaccines. Learn more about our optimised technology.
https://www.seqirus.com.au/manufacturing/technologies -
Seqirus | Technical Development
Understand our aim to develop the next generation of influenza vaccines and how we're working to unite product platforms across the globe.
https://www.seqirus.com.au/...acturing/technical-development -
Consumer Media Release
Seqirus, a CSL Company created in July 2015 from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis, is a transcontinental
https://www.seqirus.com.au/-/media/seqirus-australia/news-docs/afluria-quad-2017-consumer-release--seqirus-newsroomfinal.pdf -
Seqirus | A World Leader in Influenza Vaccines
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
https://www.seqirus.com.au/ -
Month 00, 0000
As foreshadowed in CSL's release to the Australian Securities Exchange on 31 July, closing of the transaction will allow CSL to integrate the influenza vaccines division with its
https://www.seqirus.com.au/-/media/seqirus-australia/news-docs/asx-announcement--niv-close-aug-150.pdf -
Forced Labour (Modern Slavery)
Exchange (ASX) with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza.
https://www.seqirus.com.au/-/media/seqirus/pdfs/csl-statement-on-modern-slavery-2019.pdf